Market Research Report
|Published by||Kalorama Information||Product code||355640|
|Published||Content info||155 Pages
Delivery time: 1-2 business days
|Published: March 24, 2016||Content info: 155 Pages||
Cancer Markers provides market assessment, estimate and competitive analysis for tests for oncology that use biomarkers. This includes a range of technologies made by scores of companies. These type of tests have demonstrated faster revenue growth than IVD broadly, and drawn considerable interest from competitors. The report contains products designed to determine risk for cancer, screen for cancer, test for cancer, aid in prognosis and personalize therapy. Among the technologies are the following:
Estimates for these segments are provided for 2015 and 2020. In addition, some specific marker breakouts are provided along with significant detail of products on the market.
This report reviews the progression of cancer diagnostic technologies over the past 10-15 years and notes some trends in test strategies as well, including:
Cancer Markers provides the following data:
Cancer is the number two cause of death, behind only cardiovascular disease. Cancer affects people worldwide. Every region of the world, and every country, is affected. The International Agency for Cancer, World Health Organization, reports that the estimated incidence of cancer worldwide in 2012 was 14,068,000. The most common types of cancer worldwide include breast cancer, colorectal cancer, lung cancer, and prostate cancer. These are common cancers in the United States and Europe, and are the focus of much therapeutic and diagnostic activities, and thus also the target of much of the cancer biomarker activity. It is important to remember, though, that novel biomarkers, therapies, and diagnostic tests are also being developed for other types of cancers.
This report contains company profiles, including coverage of the following:
The various clinical techniques and trends are discussed from the point of view of their present and potential market impact. Therefore, the report does not provide an in depth discussion of the etiology, physiology and clinical manifestations of diseases except where an understanding of these areas is required to understand the impact that new and early diagnostics exert on patient care. Similarly, the report does not describe the technical aspects of the test modalities used in PMx tests.
The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.